The core therapeutic profile of Оптальгин is associated with pain-relieving, fever-reducing, and spasmolytic properties. The drug is commonly used for managing symptoms associated with severe acute and chronic pain, and high fever not responding to other measures.

The medicine is relevant across domains where additional symptomatic support is needed, primarily for conditions involving intense pain, visceral spasms or cramping, and persistent high body temperature. In clinical scenarios, it is often applied for the acute discomfort after surgical procedures, in managing recurrent or episodic manifestations of colic such as renal or biliary spasms, and for persistent high body temperature in both adult and pediatric patients.

This symptomatic assistance contributes to improved comfort during periods of heightened symptomatic distress and helps maintain a sense of stability when symptoms are more noticeable.

“This support helps patients cope more steadily with difficult episodes of pain and fever.”

---

Quick Fact: Symptom Management
Primary Domain	Analgesia, Antipyresis, Spasmolysis
Pain Type	Moderate-to-severe, often spasmodic
Fever Context	High, persistent, or associated with symptomatic stress
Key Benefit	Contributes to symptom relief and patient comfort

Regulatory References

1. European Medicines Agency Assessment Report

Who Can and Cannot Use Оптальгин? (Metamizole Sodium)

The eligibility for using Metamizole sodium is defined by strict regulatory guidelines focusing on patient status and specific medical conditions. Use is generally allowed for adults and adolescents aged 15 years and older, and for pediatric patients starting from 3 months of age or mathbf5 kg body weight, with dose adjustments required.

Contraindicated Populations (Must Not Use)

The medicine is strictly contraindicated in specific groups as defined by official labeling:

• Patients with a history of agranulocytosis or other serious hematological reactions caused by Metamizole or related drugs.
• Infants under 3 months of age or weighing less than mathbf5 kg.
• Pregnant women during the third trimester. It is also not recommended during the first two trimesters.
• Individuals with impaired bone marrow function, G6PD deficiency, or acute intermittent hepatic porphyria.

Restricted and Conditional Use

Use requires caution and potential dose adjustment for patients with pre-existing hepatic impairment or renal impairment due to the risk of metabolite accumulation. Furthermore, individuals with asthma, chronic urticaria, or those with underlying severe hypotension must use the drug under restricted conditions as stated in regulatory documents.

Interactions with other medicines and products

Оптальгин (metamizole) has documented interactions with numerous other medicinal products, requiring specific precautions, monitoring, or avoidance of combination. The primary mechanism underlying several interactions is the action of metamizole as an inducer of certain metabolic enzymes, including CYP2B6 and CYP3A4.

---

Clinically Significant Interactions

Interacting Product Category	Practical Implication
Methotrexate	Co-administration should be avoided due to an increased risk of severe hematotoxicity, particularly in elderly patients.
Low-Dose Acetylsalicylic Acid (Aspirin)	Avoid simultaneous use, as metamizole may inhibit the effect of low-dose aspirin on platelet aggregation, which is critical for cardiovascular protection.
Chlorpromazine	Concomitant use may lead to severe hypothermia; requires extreme caution.
Immunosuppressants (e.g., Ciclosporin, Tacrolimus)	Plasma concentrations of these drugs should be closely monitored and adjusted, as metamizole may decrease their levels via enzyme induction.
Specific Antivirals & Psychotropics	Avoid combination with specific agents such as Sertraline, Quetiapine, and certain HIV drugs, as their effectiveness or safety profile may be affected by altered metabolism.

---

Other Important Interaction Notes

Metamizole's enzyme induction can reduce the plasma concentrations and clinical efficacy of many other drugs metabolized by CYP2B6 and CYP3A4, including Direct Oral Anticoagulants (DOACs). The combination with Oral Contraceptives should be avoided, and patients must be warned of potentially decreased contraceptive reliability for at least four weeks. Due to shared chemical properties, metamizole may interfere with the action of other pyrazolones on oral anticoagulants and certain antihypertensives. Consult a healthcare professional before combining Оптальгин with any other prescription, non-prescription, or herbal medicines.

How Optalgine Works

Optalgine is a prodrug that is rapidly hydrolyzed into its primary active metabolite, 4-methylaminoantipyrine (MAA), which permeates the blood-brain barrier. The core mechanism involves three distinct pathways at the cellular level.

Central Modulation of Prostaglandin Synthesis

Optalgine's active metabolites are proposed to function as inhibitors of the cyclooxygenase-3 (COX-3) enzyme, which is predominantly found in the central nervous system. This inhibition results in the reduction of prostaglandin E2 (PGE2) synthesis in the brain, thereby modifying signaling within the hypothalamic thermoregulatory center and nociceptive pathways.

Activation of Endogenous Systems

The mechanism also involves the activation of the endocannabinoid and opioidergic systems. Specifically, metabolites act as agonists at cannabinoid type 1 (CB1) receptors, an interaction that modulates the descending antinociceptive pathways. Additionally, MAA may influence signaling through ATP-sensitive potassium (KATP) channels.

Smooth Muscle Modulation

At a peripheral level, the drug exerts a spasmolytic effect by inhibiting the release of intracellular Ca^2+ through the reduction of inositol phosphate synthesis. This action alters the contractile state of smooth muscle tissue. The sum of these central and peripheral molecular actions results in system-level physiological modulation.

Instruction Map: How to Use Оптальгин — Official Administration Guidelines

Administration of Оптальгин (Metamizole sodium) is governed by specific parameters, outlining the required dose, frequency, and route of intake. The approved administration methods include oral use (tablets, solutions/drops), intravenous (IV) injection, intramuscular (IM) injection, and rectal use (suppositories).

Dosing Schedule and Frequency

Official instructions mandate that treatment should always start at the lowest recommended dose. For adults and adolescents (15 years of age and older, > 53 kg), a single oral dose typically ranges from 500 mg to 1,000 mg. This dose can be repeated up to four times daily, with a required minimum interval of 6 to 8 hours between doses. The maximum oral daily dose must not exceed 4,000 mg. The total daily dose for injectable forms (IV/IM) has a higher maximum limit of 5,000 mg.

Population-Specific Rules and Procedural Conditions

For pediatric patients (up to 14 years), the official single dose is calculated based on body weight, using a range of 8 mg to 16 mg of metamizole per kilogram of body weight. The initial dose should only be increased if the effect is insufficient. For older adults and patients with known kidney or liver impairment, a reduced dose and cautious approach are advised if administration is necessary. When administering the solution intravenously, the instruction is to use a slow IV injection or infusion to ensure procedural correctness.

Resulting Procedural Structure

The protocol requires beginning with the lowest effective dose, observing a mandatory 6–8 hour interval between doses, and maintaining strict adherence to the defined maximum daily doses for both oral and injectable routes. These procedural constraints establish the precise boundaries for the standardized use of Оптальгин.

Research evidence / Overview of studies for Оптальгин

---

Evidence for use in Fever (Pyrexia)

Research has evaluated Optalgin in studies focused on outcomes related to systemic or functional imbalance, specifically in people experiencing elevated body temperatures. These studies were used in research exploring how symptoms change over time following administration of the medication. The majority of this research consists of comparative trials, where Optalgin was studied for outcomes describing episodic or acute changes associated with fever.

It will focus on summarizing how researchers assessed the drug's role in outcomes related to temporary physiological imbalance. Findings describe patterns observed in the studies where patterns of lower body temperature were measured during the study period. The research has explored temporary physiological imbalance, and data show patterns related to short-term changes in temperature levels. However, results may vary depending on the underlying cause of the fever, and the evidence is limited for extremely high or persistent fevers.

---

Evidence for use in Pain Relief (Acute and Chronic Pain)

Optalgin was evaluated in various research settings involving conditions characterized by fluctuating or episodic manifestations of pain. Studies have examined research exploring outcomes related to physical discomfort, looking at outcomes related to the intensity and duration of pain that may be associated with injury or other acute conditions. Much of this evidence is derived from settings with varying symptom burdens, including trials applied in studies examining patient-reported experiences of pain levels.

The studies report how symptoms evolved in the observed populations, providing insights into short-term changes in patient-reported outcomes describing perceived discomfort. While findings indicate patterns related to patient-reported outcomes describing perceived discomfort in the groups studied, findings were mixed when comparative evidence was examined. Research is ongoing to better understand its role in different categories of pain, and comparative evidence is lacking for many specific chronic pain conditions involving periods of heightened symptoms.

---

Long-term studies and follow-up

Research concerning the use of Optalgin over extended durations is generally limited. Studies have monitored patient responses over defined time intervals, but follow-up durations were limited in many of the core trials. The available evidence is limited concerning the effects of long-term, routine use, and little data was observed in settings involving continuous administration for periods exceeding a few weeks. This section summarizes what is known and what is still uncertain about the potential for outcomes reflecting daily functioning or activity level to change after prolonged use.

---

Evidence in special populations

Optalgin was studied for use in a few specific patient groups, though evidence quality varies across studies. Research has explored its use in older adults, and some studies examined its application in children, though data for certain groups remain insufficient compared to the evidence available for the general adult population.

---

What is still uncertain about Оптальгин

The available research contributes to the broader evidence landscape, but several key areas of uncertainty remain. Research highlights changes measured during the study period, but results apply only to the populations studied, meaning findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly. The main evidence gaps include the long-term impact of its use, the consistency of findings across different racial or ethnic groups, and definitive comparative data against all alternative medications across all potential uses. Evidence quality varies across studies, and many sample sizes were modest, contributing to the fact that certainty remains low for specific complex applications.

Common questions about Оптальгин (FAQ)

---

Q: How quickly does Оптальгин start working?

Regulatory documents indicate that the onset of a pain-relieving effect may be observed between 30 and 60 minutes following the oral administration of the medicine. This time frame describes how the medicine is absorbed and becomes active in the body.

---

Q: How long does the effect of Оптальгин last?

Official dosing instructions for adults recommend that there should be a minimum interval of 6 to 8 hours between administrations. This interval is specified in official instructions to maintain the required minimum time period between administrations.

---

Q: Is Оптальгин available over the counter or only by prescription?

The regulatory status of this medicine is not uniform worldwide. In some countries, official government health bodies require it to be prescription-only, while in other regions, it may be available for sale over-the-counter. Its status depends on the specific regulatory decisions of the local health authority.

---

Q: Can Оптальгин be taken with food, or does it need to be taken on an empty stomach?

Product information often suggests that the tablets can be taken with food or milk. This approach is described in product information and may be used to minimize potential gastrointestinal discomfort.

---

Q: Does Оптальгин cause drowsiness or affect the ability to drive?

Official sources list somnolence (drowsiness) and vertigo (a feeling of spinning or dizziness) as common adverse events. Official warnings note that individuals experiencing these effects should not drive or operate machinery.

---

Q: Can I take Оптальгин if I have high blood pressure?

Regulatory documents indicate that the medicine may reduce the clinical effects of certain blood pressure medications (antihypertensives). Furthermore, the drug is contraindicated for individuals with pre-existing severe low blood pressure (hypotension). Because of these potential effects, the use of this medicine in individuals with high blood pressure is typically managed under restricted conditions.

---

Q: Are there any known issues with taking Оптальгин and alcohol?

Product safety reviews typically state that the combination of the medicine with alcohol should be avoided. This is based on the potential for alcohol to increase the risk of certain side effects, particularly those affecting the gastrointestinal system.

---

Q: Does Оптальгин have an effect on stomach lining or ulcers?

Research indicates that this medicine has a distinct profile compared to most NSAIDs regarding gastrointestinal side effects. However, some official reviews have indicated a measured risk of upper gastrointestinal bleeding compared to non-use.

---

Q: What happens if a dose of Оптальгин is missed?

Standard guidance described in patient information states that if a dose is missed, it should generally be skipped if it is almost time for the next scheduled dose. Official information indicates that taking a double dose to compensate for a missed one is not recommended.

---

Q: Does the manufacturer of Оптальгин provide information about its use in breastfeeding?

Official recommendations state that the use of this medicine during breastfeeding is not recommended. This caution is due to the potential for the active metabolites of the drug to be transferred to the infant.

---

Q: Is it normal to feel a mild headache after starting Оптальгин?

Official literature regarding adverse events lists headache as a common adverse event associated with the use of this medicine. Official literature simply lists headache as a common adverse event.

---

Q: What is considered an overdose of Оптальгин according to the literature?

In regulatory literature, overdose is linked to severe effects including nausea, vomiting, and kidney impairment (renal impairment). More serious outcomes described in the literature include convulsions, shock, and severe drops in body temperature (hypothermia).

---

Q: Is there a risk of addiction or dependence with Оптальгин?

Official pharmacological classifications define this medicine as a non-opioid analgesic. Due to this classification, the medicine is not associated with the same risk of addiction or physical dependence that is characteristic of opioid-based pain medications.

Storage and Disposal of Optalgin

Official regulatory guidelines require that Optalgin (metamizole sodium) be stored at a temperature not exceeding 25 C and be maintained in a dry environment. The product must be stored in its original package to ensure protection from light, and storage in the freezer is prohibited. For multi-dose forms, stability may be limited after the initial opening, and diluted solutions must be used immediately.

All medicine must be secured out of the sight and reach of children and kept in a locked location. When disposing of unused or expired Optalgin, the preferred method is to utilize an authorized drug take-back program. Disposal must avoid release to the environment, and the medicine should not be flushed down drains. If take-back is unavailable, the product should be mixed with an undesirable substance (e.g., used coffee grounds) before being placed in the household trash, with all personal information removed from the packaging.